Breakout Sessions : Humans-in-a-Dish: Hope or Hype?

jun 3, 2019: 4 p.m. - 5 p.m.
105AB, Level 100

Despite advances in many drug research paradigms - DNA sequencing, high throughput screening and CRISPR - success rates in drug development have remained largely unchanged. An estimated $2.6B and 12 years are spent bringing a drug to market, due largely to the industry%u2019s reliance on ineffective animal models. The gap between the benchtop and bedside is wide, but Organ-on-a-Chip technology and microphysiological systems (MPS) show promise to bridge the divide. Expectations range from replacing animal testing and clinical trials in a dish to personalized medicine, but what can we realistically expect in the next 3-5 years? This panel will summarize the potential for novel alternatives to animal testing, as well as define limitations and the need to set expectations.


William Mattes
Director, Divisions of...

Matthew Wagoner
Investigative Toxicolo...

Matt Gevaert
CEO & Co-founder

Bo Yeon Lee
Scientific Program Man...